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Abstract
Background: Phenobarbital and midazolam are commonly 
used drugs in (near-)term neonates treated with therapeutic 
hypothermia for hypoxic-ischaemic encephalopathy, for se-
dation, and/or as anti-epileptic drug. Phenobarbital is an in-
ducer of cytochrome P450 (CYP) 3A, while midazolam is a 
A complete list of non-author contributors appears in the Acknowl-
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CYP3A substrate. Therefore, co-treatment with phenobarbi-
tal might impact midazolam clearance. Objectives: To assess 
pharmacokinetics and clinical anti-epileptic effectiveness of 
phenobarbital and midazolam in asphyxiated neonates and 
to develop dosing guidelines. Methods: Data were collected 
in the prospective multicentre PharmaCool study. In the 
present study, neonates treated with therapeutic hypother-
mia and receiving midazolam and/or phenobarbital were in-
cluded. Plasma concentrations of phenobarbital and mid-
azolam including its metabolites were determined in blood 
samples drawn on days 2–5 after birth. Pharmacokinetic 
analyses were performed using non-linear mixed effects 
modelling; clinical effectiveness was defined as no use of ad-
ditional anti-epileptic drugs. Results: Data were available 
from 113 (phenobarbital) and 118 (midazolam) neonates; 68 
were treated with both medications. Only clearance of 1-hy-
droxy midazolam was influenced by hypothermia. Pheno-
barbital co-administration increased midazolam clearance 
by a factor 2.3 (95% CI 1.9–2.9, p < 0.05). Anticonvulsant ef-
fectiveness was 65.5% for phenobarbital and 37.1% for add-
on midazolam. Conclusions: Therapeutic hypothermia does 
not influence clearance of phenobarbital or midazolam in 
(near-)term neonates with hypoxic-ischaemic encephalopa-
thy. A phenobarbital dose of 30 mg/kg is advised to reach 
therapeutic concentrations. Phenobarbital co-administra-
tion significantly increased midazolam clearance. Should 
phenobarbital be substituted by non-CYP3A inducers as 
first-line anticonvulsant, a 50% lower midazolam mainte-
nance dose might be appropriate to avoid excessive expo-
sure during the first days after birth.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Hypoxic-ischaemic encephalopathy (HIE) caused by 
perinatal asphyxia is a serious clinical condition with sig-
nificant morbidity and mortality in (near-)term neo-
nates. Globally, the incidence varies between 0.5 and 20 
of every 1,000 live born neonates [1]. Therapeutic hypo-
thermia (TH) is an established neuroprotective treatment 
which has markedly reduced the composite adverse out-
come of death and neurodevelopmental disorders. In the 
Netherlands, 150–200 neonates are eligible for this treat-
ment annually [2, 3].
Phenobarbital and midazolam are commonly pre-
scribed drugs in this vulnerable population. Phenobarbi-
tal is a first-line anti-epileptic drug (AED). It acts through 
stimulation of the γ-aminobutyric acid (GABA) receptors 
in the central nervous system, which leads to a postsynap-
tic increase in chloride ions, thereby reducing neuronal 
excitability [4]. Phenobarbital has a half-life of approxi-
mately a week in neonates. Therefore, it can be adminis-
tered as single or rapidly consecutive bolus administra-
tions up to 40 mg/kg. Plasma concentrations between 20 
and 40 mg/L are considered effective and safe [5]. Mid-
azolam is a benzodiazepine which also interacts with the 
GABA receptor. It is used as a second-line AED when phe-
nobarbital is ineffective [6]. Additionally, it is used for se-
dation for instance in neonates who require mechanical 
ventilation [7]. Midazolam has a relatively short half-life 
of several hours in neonates and is usually administrated 
via continuous infusion. For sedation, doses around 0.1 
mg/kg/h are often sufficient, while as an AED, doses up to 
or even exceeding 0.3 mg/kg/h have been used. The thera-
peutic window for midazolam is not well defined but plas-
ma concentrations of at least 0.1 mg/L are required for 
both indications. Higher plasma concentrations are asso-
ciated with increased AED effectiveness [8]. Levels above 
2.4 mg/L are considered toxic [9].
Midazolam undergoes hepatic metabolism by cyto-
chrome P450 (CYP) 3A into 1-hydroxymidazolam 
(OHM). OHM is further metabolised into hydroxymid-
azolam glucuronide (HMG) which is excreted renally. 
Both metabolites are pharmacologically active, and accu-
mulation has been associated with prolonged sedation 
[10, 11]. Phenobarbital is known as a potent inducer of 
several CYP enzymes in adults, including CYP3A [12].
Pharmacokinetics (PK) of drugs in neonates differs 
from older children and adults due to immaturity of the 
involved organs. CYP expression is impaired at birth but 
is subject to (rapid) maturation in the first few days of life 
[13, 14]. Midazolam clearance could potentially be in-
creased if phenobarbital is also administered, but it is un-
certain whether this drug-drug interaction is present in 
neonates. Induction of midazolam clearance might have 
important consequences for the use of this drug in this 
population since adequate control of neonatal seizures is 
important to reduce the risk of neurological disabilities 
[15–17].
Hypothermia could influence various physiological 
processes relevant for PK such as organ perfusion, pro-
tein binding, and (metabolic) enzymatic activity [18–20]. 
Previous studies from our group have assessed the effect 
of TH on PK of both phenobarbital and midazolam in this 
population using data from two tertiary neonatal inten-
sive care units (NICU) as well as clinical effectiveness as 
AED [5, 8]. Clearance of neither drug was found to be af-
fected by TH. Sufficient seizure control was achieved in 
66% of all neonates with phenobarbital monotherapy. 
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When midazolam was started as a second-line AED, ef-
fectiveness was 23%.
The objective of the present study was to expand the 
current PK knowledge of phenobarbital and midazolam 
in neonates undergoing TH as treatment for HIE, to eval-
uate the previously developed models with an external 
dataset, to assess the effectiveness of each AED, and to 
develop PK-based dosing guidelines. In post hoc analy-
ses, the influence of phenobarbital co-administration on 
midazolam clearance was investigated.
Methods
Setting and Study Population
The multi-centre prospective study PharmaCool was designed 
to investigate the PK of frequently used drugs during TH and re-
warming in neonates suffering from HIE. Inclusion and exclusion 
criteria have been described previously [21]. Parental informed 
consent was obtained in all cases. The choice of therapy and drug 
dosing was not influenced by the study protocol. The PharmaCool 
study was approved by the Ethics Committees of all twelve par-
ticipating NICUs in the Netherlands and Belgium.
Dosing and Administration
Phenobarbital was dosed as a single or repeated bolus short in-
fusion of 10 of 20 mg/kg, up to a cumulative dose of 40 mg/kg. 
Midazolam was administrated as continuous infusion, both for se-
dation and as AED, with a starting dose of 0.05 mg/kg/h for seda-
tion and 0.1 mg/kg/h for seizure control and titrated to effect. Both 
regimens can be preceded by a loading dose of 0.05–0.1 mg/kg.
Sampling and Bioanalysis
Blood samples were drawn once daily on days 2–5 after birth 
both during hypothermia and rewarming/normothermia [21]. 
Plasma concentrations of phenobarbital, midazolam, OHM, and 
HMG were determined using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). Details are available in the online 
Appendix (see www.karger.com/doi/10.1159/000/499330 for all 
online suppl. material).
Population Pharmacokinetic Analyses
PK analyses were performed using non-linear mixed effects 
modelling NONMEM (version 7.3, Icon Development Solutions) 
[22]. Birth weight was used as a descriptor for body size and was 
related to pharmacokinetic parameters using allometric relation-
ships. Based on previous publications from our group, a one-com-
partment model for phenobarbital and a one-compartment model 
for midazolam with consecutive one-compartment models for 
both metabolites were used as structural models [5, 8]. Gestation-
Table 1. Patient characteristics
Parameter Phenobarbital (n = 113) Midazolam (n = 118)
PB yes (n = 68) PB no (n = 50)
Gestational age, weeks 39.8±1.7 40.2±1.4 39.8±1.6
Birth weight, g 3,382±582 3,450±540 3,495±674
Male 63 (55.8) 35 (51.5) 36 (72)
pHa 7.02 (6.85 to 7.15) 6.98 (6.80 to 7.10) 6.90 (6.80 to 7.05)
Lactatea, mmol/L 13.0 (9.0 to 18.2) 14.1 (11.4 to 16.6) 12.0 (7.8–14.6)
Base excessa, mmol/L –18.0 (–12.0 to –22.0) –18.0 (–22.0 to –12.0) –18.5 (–21 to –14.3)
Thompson scoreb 9 (8–13) 10 (8 to 14) 9 (7–10)
Midazolam sedation only – 33 (48.3) 50 (100)
Midazolam AED – 35 (51.5) 0 (0)
aEEG on admissionb
Continuous normal voltage 16 (14.2) 8 (11.8) 10 (20.0)
Discontinuous normal voltage
Of whom <5 µV
45 (39.8)
16 (14.2)
20 (29.4)
9 (13.2)
29 (58.0)
14 (28.0)
Burst suppression 26 (23.0) 21 (30.9) 6 (12.0)
Continuous low voltage 5 (4.4) 4 (5.9) 1 (2.0)
Flat trace 17 (15.0) 13 (19.1) 1 (2.0)
Unknown 4 (3.5) 2 (2.9) 3 (6.0)
Mortality 32 (28.3) 27 (39.7) 1 (2.0)
Data are presented as mean ± standard deviation, median (interquartile range), or n (%). PB, phenobarbital co-medication; AED, 
anti-epilpetic drug; aEEG, amplitude-integrated electroencephalogram. a Value measured in umbilical cord blood or, if unavailable, from 
arterial or venous blood within 1 h after birth. b Encephalopathy was characterized by a Thompson score of >7 1 h after birth or an 
abnormal aEEG (i.e., background pattern DNV <5 μV or worse or seizures) on admission to a level III NICU.
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al age (GA), postnatal age (PNA), and body temperature (TEMP) 
were tested as covariates on clearance in both models. Phenobar-
bital co-medication was tested as covariate on clearance in the 
midazolam model. Parameter precision was assessed with sam-
pling importance resampling [23].
Anticonvulsant Effectiveness
Treatment with phenobarbital was considered effective if no 
additional AED was started. In patients receiving midazolam for 
seizure control, effectiveness as second-line AED was defined as 
no requirement for a third-line AED.
Dosing Guideline Development
Several dosing regimens based on the current clinical practice 
were simulated using the parameter estimates of the final pharma-
cokinetic models. Phenobarbital single doses of 20, 30, and 40 mg/
kg were evaluated. Midazolam was tested with a loading dose of 
0.05 or 0.1 mg/kg followed by continuous infusions varying be-
tween 0.05 and 0.3 mg/kg/h.
Results
Patient Characteristics
Phenobarbital data were available for 113 patients. Cu-
mulative doses varied between 4.9 and 62.6 mg/kg. Mid-
azolam data were available from 118 patients (sedative 
n = 83, AED n = 35). Of these, 68 (57.6%) were also treat-
ed with phenobarbital. Midazolam maintenance dose for 
sedation rarely exceeded 0.15 mg/kg/h. Highest midazo-
lam maintenance dose as AED was 0.45 mg/kg/h. Patient 
characteristics are presented in Table 1.
Phenobarbital plasma concentrations were measured 
in 378 samples of which 219 (57.9%) were taken during 
TH. Plasma concentrations varied between 9.1 and 52.6 
mg/L (Fig.  1). Plasma concentrations of midazolam, 
OHM and HMG were measured in 376 samples, of 
which 214 (56.9%) were taken during TH. Plasma con-
centrations for midazolam varied between 0.02 and 3.25 
mg/L (Fig. 2), for OHM between 0.02 and 1.05 mg/L, and 
for HMG between 0.02 and 8.34 mg/L (online Appen-
dix).
Population Pharmacokinetic Analyses
Phenobarbital PK was best described by a one-com-
partment model. No influence of GA, PNA or TEMP 
could be detected on clearance. Midazolam PK was de-
scribed by a one-compartment model with subsequent 
one-compartment models for OHM and HMG. GA and 
PNA did not affect clearance of any compound; TEMP 
significantly influenced only OHM clearance; clearance 
during TH was reduced by 25.7% (p < 0.05, 8.6%/° C, 
95% CI 5.6–11.5%/° C). Phenobarbital co-medication 
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significantly influenced midazolam clearance. In ab-
sence of phenobarbital, midazolam clearance for a neo-
nate of 3.5 kg was 0.35 L/h (95% CI 0.29–0.41 L/h). In 
patients with phenobarbital co-medication, midazolam 
clearance was 2.3-fold higher (p < 0.05, 95% CI 1.9–2.9). 
This effect was consistent over the entire study period 
and independent of phenobarbital dose, TH, or indica-
tion for midazolam use. Pharmacokinetic parameter es-
timates of the final models are shown in Table 2. Further 
details of the population PK analyses are available in the 
online Appendix.
Anticonvulsant Effectiveness
Seizure control with phenobarbital monotherapy was 
achieved in 74 patients (65.5%). Thirty-five patients re-
ceived midazolam as second-line AED. Of these, 22 
(62.9%) also received lidocaine, levetiracetam, and/or 
clonazepam as additional AED. Midazolam was consid-
ered effective in the remaining 13 (37.1%) neonates. AED 
effectiveness is summarised in Table 3.
Dosing Guideline Development
Simulation datasets were created by replicating the patient 
characteristics of each neonate in the original dataset nine 
times, yielding simulation datasets of 1,017 patients for phe-
nobarbital and 1,062 patients for midazolam. These datasets 
were used with the final PK parameter estimates to predict 
plasma concentrations after various dosing regimens.
Figure 3 shows predicted phenobarbital concentra-
tion-time curves after doses of 20, 30, and 40 mg/kg at 
PNA 4 h. With 20 mg/kg, 46.7% of patients are within the 
proposed therapeutic range (20–40 mg/kg) directly after 
bolus infusion, dropping to 18.7% at PNA 48 h. 30 mg/kg 
results in 90.2% within the therapeutic range directly after 
infusion and 85.4% at PNA 48 h. A dose of 40 mg/kg leads 
to 53.2% within the therapeutic range directly after infu-
sion and 80.7% at PNA 48 h.
Figure 4 shows predicted concentration-time curves of 
midazolam with and without phenobarbital co-adminis-
tration after a loading dose of 0.1 mg/kg followed by con-
tinuous infusion of 0.15 mg/kg/h. 
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Discussion
Data from this study confirm the previous findings that 
TH does not influence phenobarbital or midazolam clear-
ance in neonates suffering from HIE. Clearance of OHM is 
reduced during TH compared to normothermia; clinicians 
should be aware that prolonged sedation could occur after 
cessation of midazolam during TH. Phenobarbital co-med-
ication was found to significantly increase midazolam 
clearance. Although this effect has not been described pre-
viously, it has most likely been present in clinical practice 
for decades as both midazolam and phenobarbital are com-
monly used in neonates, often concomitantly for the treat-
ment of seizures. Midazolam is usually titrated to the de-
sired effect and/or tolerability of side effects independent of 
concomitant treatment with phenobarbital. Although ad-
equate sedation and seizure control are crucial in neonates 
undergoing TH for HIE, concerns have been raised about 
both phenobarbital and midazolam use. Phenobarbital has 
been associated with neuronal toxicity in neonatal animal 
models and long-term cognitive and motor impairment in 
humans. Therefore, alternative first-line AEDs such as le-
vetiracetam are currently being investigated [24]. As leve-
tiracetam does not induce CYP3A, no influence on mid-
azolam clearance is expected. In this situation, a reduction 
in midazolam maintenance dose by 50% is necessary to 
achieve similar plasma concentrations. Overexposure of 
midazolam should be avoided to minimise the risk of side 
effects such as hypotension and subsequent cerebral hypo-
perfusion when cerebral autoregulation is lost, and pro-
longed NICU admission [6, 8, 25, 26].
CYP3A is the most abundant subfamily of cytochrome 
P450 isozymes in the human liver and consists of at least 
three isoforms: CYP3A4, CYP3A5, and CYP3A7 [27]. 
CYP3A4 activity is relatively low at birth but increases 
over the first few weeks of life and reaches adult capacity 
between 6–12 months after birth. In adult livers, it ac-
counts for 30–40% of all CYP content [27, 28]. CYP3A5 
is present at a much lower level compared to CYP3A4 and 
shows large interindividual variability. No maturational 
pattern of CYP3A5 has been identified [28]. CYP3A7 is 
Table 2. Final model pharmacokinetic parameter estimates and SIR results
Parameter Phenobarbital Midazolam OHMa HMGa
estimate SIRb 95% CI estimate SIRc 95% CI estimate SIRc 95% CI estimate SIRc 95% CI
Cl, L/hd 10.3 8.38–12.1 0.353 0.286–0.441 3.39 2.75–4.01 0.191 0.170–0.214
V, Ld 3.60 3.43–3.79 5.42 4.49–6.81 4.18 (fixed) NA (fixed) 1.06 0.834–1.27
TEMP on Cl, %/° C NA NA NA NA 8.58 5.63–11.5 NA NA
PB on Cl, fold NA NA 2.33 1.88–2.92 NA NA NA NA
Interindividual variability
Cl, variance (rsd) 0.287 (54%) 0.148–0.498 0.628 (79.2%) 0.479–0.847 0.633 (79.6%) 0.472–0.818 0.241 (49.1%) 0.174–0.338
V, variance (rsd) 0.0442 (36%) 0.0305–0.0659 0.934 (96.6%) 0.583–1.27 NA (fixed) NA (fixed) 0.837 (91.5%) 0.353–1.33
Residual variability
Additional, mg/L (rse) 2.52 (31%) 2.32–2.79 0.01 (fixed) NA (fixed) 0.01 (fixed) NA (fixed) 0.01 (fixed) NA (fixed)
Proportional, variance (rsd) NA NA 0.126 (35.5%) 0.107–0.164 0.0857 (29.3%) 0.0683–0.119 0.0871 (29.5%) 0.0729–0.112
Covariance interindividual variability on Cl Midazolam/OHM Midazolam/HMG OHM/HMG
estimate SIRc 95% CI estimate SIRc 95% CI estimate SIRc 95% CI
Covariance (correlation coefficient) 0.500 (79.0%) 0.378–0.652 0.214 (55.0%) 0.133–0.310 0.233 (60.0%) 0.147–0.327
Cl, clearance; V, volume of distribution; TEMP, body temperature; PB, phenobarbital co-medication; OHM, 1-hydroxymidazolam; HMG, hydoxymidazolam glucuronide; SIR, sampling importance resampling; 
NA, not applicable; rsd, relative standard deviation; rse, relative standard error. a All metabolite estimates are relative to formation fraction FOHM and FHMG, resp. b Five iterations; no. of samples 4,000, 4,000, 4,000, 
4,000, 4,000; no. of resamples 1,000, 1,000, 1,000, 1,000, 2,000; c Six iterations, no. of samples 4,000, 4,000, 4,000, 4,000, 4,000, 4,000; no. of resamples 1,000, 1,000, 1,000, 1,000, 1,000, 1,000; d Estimates for neonate 
with a birth weight of 3.5 kg.
Table 3. Effectiveness of phenobarbital and midazolam as anti-
epileptic drugs
Effective Ineffective
Phenobarbital (n = 113) 74 (65.5) 39a (34.5)
Midazolam (n = 35) 13 (37.1) 22  (62.9)
Data are presented as n (%). a Four patients unresponsive to 
phenobarbital received lidocaine instead of midazolam as second-
line anti-epileptic drug.
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the major CYP isoform detected in the embryonic, foetal, 
and newborn liver but decreases thereafter. Compounds 
metabolised by CYP3A4 in adults are most likely primar-
ily metabolised by CYP3A7 in neonates and infants up to 
3 months of age [28, 29].
Induction of CYP enzymes is caused by an increase in 
gene transcription followed by upregulation of enzyme 
production. Unlike CYP inhibition, which is an almost 
immediate response, it is believed that CYP induction is 
a slower regulatory process which accumulates over time 
[30]. In adults, clinically relevant CYP3A induction has 
been described within 24 h after administration [31]. In 
asphyxiated neonates, both phenobarbital and midazol-
am are often administered within the first few hours after 
birth. In this study, blood sampling commenced on the 
second day after birth. As a time-dependent effect of 
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Fig. 3. Simulated phenobarbital plasma concentrations after a dose of 20 mg/kg (a), 30 mg/kg (b), and 40 mg/kg 
(c). Solid lines indicate the mean phenobarbital plasma concentrations. Dotted lines indicate the proposed ther-
apeutic window; grey area represents the 95% prediction interval.
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phenobarbital on midazolam clearance was not identi-
fied, we hypothesise that the increasing effect of pheno-
barbital on CYP3A production in this population is clin-
ically relevant as early as 24 h after birth.
In the past, phenobarbital has been used to treat hyper-
bilirubinaemia in predominantly preterm infants by in-
ducing glucuronidation of unconjugated bilirubin [32]. 
Although OHM is glucuronated into HMG, no effect of 
phenobarbital co-medication on OHM clearance was 
identified. It is possible that glucuronidation is more de-
veloped in term neonates and that induction of glucuron-
idation is only relevant in preterm neonates as phenobar-
bital was unsuccessful in preventing hyperbilirubinaemia 
in term neonates [33]. Also, to our knowledge no drug-
drug interactions between phenobarbital and drugs un-
dergoing glucuronidation have been described in humans.
Table 1 clearly shows a difference in baseline character-
istics between midazolam patients with and without pheno-
barbital co-administration. Neonates with phenobarbital 
co-medication had a more suppressed aEEG on admission 
and higher mortality, suggesting a more severe disease state. 
However, increased midazolam clearance in this group by 
induction of CYP3A indicates that hepatic metabolic capac-
ity is unaffected even in the most severe HIE cases.
Based on simulations performed in this study, a phe-
nobarbital loading dose of 30 mg/kg is recommended to 
achieve plasma concentrations within the therapeutic 
window. An additional dose of 10 mg/kg can be given if 
seizures persist. This advice is in line with a recent study 
investigating phenobarbital PK in non-asphyxiated term 
and preterm neonates [34]. Phenobarbital effectiveness is 
comparable to previous reports [4, 5].
No changes to the midazolam dosing regimens are re-
quired in the current clinical practice. However, should 
phenobarbital be replaced as first-line AED, midazolam 
for additional seizure control should be titrated more 
carefully. Although responsiveness to midazolam in this 
study was higher than previously reported, its effective-
ness as second-line AED remains limited [4, 8].
The data for this study were collected in neonates with 
a GA of ≥36 weeks treated with TH for HIE. However, we 
believe that the interaction between phenobarbital and 
midazolam can be extrapolated to (near-)term neonates in 
general. As liver function might be hampered by TH and/
or HIE, the magnitude of the effect in non-asphyxiated nor-
mothermic neonates could be even greater. Extrapolation 
to preterm neonates should be done with caution due to 
possible maturational differences in CYP enzymes [13].
Conclusion
PK of phenobarbital and midazolam is unaffected by 
TH in (near-)term neonates treated with TH for HIE, and 
clinical effectiveness is comparable to previous reports. 
Phenobarbital significantly increased midazolam clear-
ance. Should phenobarbital be substituted by non-CYP-
inducing drugs as first-line anticonvulsant, a lower mid-
azolam dose is necessary to avoid excessive exposure 
across the entire neonatal population.
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Fig. 4. Simulated midazolam plasma concentrations after a loading 
dose of 0.1 mg/kg followed by continuous infusion of 0.15 mg/kg/h. 
Upper solid line indicates the mean midazolam plasma concentra-
tion without phenobarbital co-medication. Bottom solid line indi-
cates the mean midazolam plasma concentration with phenobarbi-
tal co-medication; grey areas represent the interquartile ranges.
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